GSK uses AI in three projects to expand knowledge of oncohematological diseases
GSK has incorporated artificial intelligence and natural language processing into three real-world evidence projects, through which it has enriched anonymized clinical information from more than 20,500 patients. Reveal-MN analyzes data from about 3,400 patients with multiple myeloma; Tatiana, from 546 patients with advanced or relapsed endometrial cancer; and Horion, from more than 16,500 patients with solid and hematological tumors to study the impact of herpes zoster. Spanish hospitals such as 12 de Octubre, Sant Pau, del Mar and Clínica Universidad de Navarra take part in the studies.
In 35 seconds
- GSK applies AI and natural language processing to electronic health records in three real-world evidence projects.
- Reveal-MN examines clinical data from about 3,400 patients with multiple myeloma.
- Tatiana analyzes 546 patients with advanced or relapsed endometrial cancer.
IASummary generated by artificial intelligence from a story by iSanidad. It may contain errors: the original source prevails.





Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.